Literature DB >> 10353732

Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas.

H Achiwa1, Y Yatabe, T Hida, T Kuroishi, K Kozaki, S Nakamura, M Ogawa, T Sugiura, T Mitsudomi, T Takahashi.   

Abstract

Recently, we demonstrated that elevated expression of cyclooxygenase 2 (COX-2) is frequently seen in a specific type of lung cancer, i.e., adenocarcinoma, and is possibly associated with its invasion and metastasis. Here, the prognostic significance of elevated COX-2 expression was evaluated in a cohort of 130 adenocarcinoma patients who had consecutively undergone potentially curative resections. Immunohistological examination showed the presence of tumor cells with markedly increased COX-2 immunoreactivity in 93 of 130 (72%) cases. No relationship was found between the increase in COX-2 expression and clinical outcomes when the entire cohort was considered (P = 0.099). Reasoning that the influence of the increase in COX-2 expression may have been obscured by the clinical and molecular pathogenetic complexities in cases with an advanced disease, we also separately analyzed the prognostic significance of increased COX-2 expression after stratification according to the disease stage. A significant relationship between elevated COX-2 expression and shortened patient survival was observed only in a cohort of patients with stage I disease (P = 0.034). These findings suggest that an increase in COX-2 expression may be clinically significant for the prognosis of patients undergoing surgical resection of early-stage adenocarcinomas and, thus, warrant further conclusive studies involving a larger cohort.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10353732

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  59 in total

1.  National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms.

Authors:  Daniel H Hwang; Victor Fung; Andrew J Dannenberg
Journal:  Neoplasia       Date:  2002 Mar-Apr       Impact factor: 5.715

Review 2.  Myeloid suppressor cells and immune modulation in lung cancer.

Authors:  Minu K Srivastava; Åsa Andersson; Li Zhu; Marni Harris-White; Jay M Lee; Steven Dubinett; Sherven Sharma
Journal:  Immunotherapy       Date:  2012-03       Impact factor: 4.196

3.  Cyclooxygenase-2 gene and lung carcinoma risk.

Authors:  Ender Coskunpinar; Ilhan Yaylim Eraltan; Akif Turna; Bedia Agachan
Journal:  Med Oncol       Date:  2010-07-20       Impact factor: 3.064

4.  Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44.

Authors:  M Dohadwala; J Luo; L Zhu; Y Lin; G J Dougherty; S Sharma; M Huang; M Pold; R K Batra; S M Dubinett
Journal:  J Biol Chem       Date:  2001-04-24       Impact factor: 5.157

5.  COX-2 inhibitors in NSCLC: never-ending story or misplaced?

Authors:  Alex Martinez-Marti; Alejandro Navarro; Enriqueta Felip
Journal:  Transl Lung Cancer Res       Date:  2018-09

6.  Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer.

Authors:  Jan Brabender; JiMin Park; Ralf Metzger; Paul M Schneider; Reginald V Lord; Arnulf H Hölscher; Kathleen D Danenberg; Peter V Danenberg
Journal:  Ann Surg       Date:  2002-03       Impact factor: 12.969

7.  COX-2/EGFR expression and survival among women with adenocarcinoma of the lung.

Authors:  Alison L Van Dyke; Michele L Cote; Geoffrey M Prysak; Gina B Claeys; Angie S Wenzlaff; Valerie C Murphy; Fulvio Lonardo; Ann G Schwartz
Journal:  Carcinogenesis       Date:  2008-05-02       Impact factor: 4.944

Review 8.  15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer.

Authors:  Hsin-Hsiung Tai; Min Tong; Yunfei Ding
Journal:  Prostaglandins Other Lipid Mediat       Date:  2007-01-17       Impact factor: 3.072

9.  Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Ping Zhan; Qian Qian; Li-Ke Yu
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

10.  Combination Therapy of PPARgamma Ligands and Inhibitors of Arachidonic Acid in Lung Cancer.

Authors:  Jordi Tauler; James L Mulshine
Journal:  PPAR Res       Date:  2009-03-04       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.